Patient Square Capital LP Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Patient Square Capital LP acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 325,789 shares of the company's stock, valued at approximately $7,320,000. Nurix Therapeutics makes up about 2.7% of Patient Square Capital LP's holdings, making the stock its 6th largest position. Patient Square Capital LP owned about 0.46% of Nurix Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Amalgamated Bank grew its holdings in shares of Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock worth $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock worth $54,000 after acquiring an additional 559 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company's stock worth $101,000 after acquiring an additional 4,119 shares during the period. GAMMA Investing LLC grew its holdings in shares of Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock worth $95,000 after acquiring an additional 3,424 shares during the period. Finally, Quest Partners LLC grew its holdings in shares of Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after acquiring an additional 1,312 shares during the period.

Nurix Therapeutics Trading Down 0.3 %

NASDAQ:NRIX traded down $0.07 during mid-day trading on Wednesday, hitting $20.82. The company had a trading volume of 715,131 shares, compared to its average volume of 900,989. The business has a fifty day simple moving average of $23.90 and a 200-day simple moving average of $21.92. Nurix Therapeutics, Inc. has a 1 year low of $7.18 and a 1 year high of $29.56. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -7.18 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. HC Wainwright upped their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Jefferies Financial Group started coverage on Nurix Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $41.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $29.00 target price on shares of Nurix Therapeutics in a report on Wednesday, November 6th. Royal Bank of Canada lowered their target price on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating on the stock in a report on Monday, October 14th. Finally, Stephens reiterated an "overweight" rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, October 14th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $29.40.

Insider Buying and Selling

In other news, insider Christine Ring sold 3,290 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $614,800. The trade was a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,401 shares of company stock worth $437,453. Corporate insiders own 9.80% of the company's stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.